Table 3 Per Cohort grades and relation of all adverse events

From: Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial

Grade

Cohort 6

Cohort 5

Cohort 4

Cohort 3

Cohort 2

Cohort 1

1-Mild

24 (64.9)

12 (70.6)

12 (60)

22 (84.6)

23 (67.6)

21 (84)

2-Moderate

10 (27)

3 (17.6)

4 (20)

4 (15.4)

9 (26.5)

4 (16)

3-Severe

3 (8.1)

2 (11.8)

4 (20)

0 (0)

2 (5.9)

0 (0)

Totals

37

17

20

26

34

25

Relation

Cohort 6

Cohort 5

Cohort 4

Cohort 3

Cohort 2

Cohort 1

Definite

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (4)

Possible

12 (32.4)

3 (17.6)

3 (15)

0 (0)

0 (0)

2 (8)

Probable

1 (2.7)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Unlikely

14 (37.8)

7 (41.2)

3 (15)

1 (3.8)

0 (0)

3 (12)

Unrelated

10 (27)

7 (41.2)

14 (70)

25 (96.2)

34 (100)

19 (76)

Totals

37

17

20

26

34

25